<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885907</url>
  </required_header>
  <id_info>
    <org_study_id>21-5324.0</org_study_id>
    <nct_id>NCT04885907</nct_id>
  </id_info>
  <brief_title>Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients</brief_title>
  <official_title>A Randomised, Blinded, Controlled Trial of a Third Dose of Moderna COVID-19 Vaccine Versus Placebo in Solid Organ Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized, double-blind, placebo-controlled trial of a third dose of&#xD;
      Moderna vaccine versus placebo. Participants will be those that have received two doses of&#xD;
      mRNA-1273 COVID vaccine (Moderna) at 0 and 1 months. Participants will be randomized 1:1 to&#xD;
      receive either a third dose of the mRNA-1273 vaccine or saline placebo at 3 months post&#xD;
      initial vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Solid organ transplant (SOT) recipients are at high risk of COVID-19 complications. The&#xD;
      Moderna vaccine (mRNA-1273) has proven highly efficacious and safe in a phase III large,&#xD;
      randomized controlled trial of 30,420 persons in the general population, and has been in use&#xD;
      in Canada since December 2020. SOT patients show diminished response to mRNA vaccines in&#xD;
      several studies with approximately 40-50% positive antibody after the second dose. In&#xD;
      positive patients, antibody titers are lower than the general population and adverse events&#xD;
      mirror the general population. The current study will recruit 120 SOT recipients who have&#xD;
      received both scheduled doses of the Moderna vaccine at 0 and 1 months. The hypothesis is&#xD;
      that a third dose of vaccine will significantly increase antibody titers. SOT participants&#xD;
      will be recruited and randomized 1:1 to receive an additional dose of Moderna COVID-19&#xD;
      vaccine two months after the last dose vs saline placebo. The outcomes will measure anti-RBD&#xD;
      antibody titer, T-cell immunity, local/systemic side effects, and rejection events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Participant and vaccinator will be blinded to vaccine vs placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>anti-RBD antibody titer</measure>
    <time_frame>4-6 weeks after intervention</time_frame>
    <description>Percentage of patients that achieve anti-RBD of &gt;=100 U/mL in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7 days after intervention</time_frame>
    <description>Percentage of patient with local and systemic adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell response</measure>
    <time_frame>4-6 weeks after intervention</time_frame>
    <description>Proportion of participants with an increase in polyfunctional T-cell response compared to pre-vaccination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SARS-CoV-2 infection</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>Number of patients with microbiologically proven infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Rejection</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <description>Proportion of patients with biopsy-proven or clinically treated graft rejection</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Vaccine Response Impaired</condition>
  <condition>Immune Suppression</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273 vaccine</intervention_name>
    <description>COVID vaccine 3rd dose</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Moderna COVID-19 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline Placebo</intervention_name>
    <description>Normal Saline Placebo</description>
    <arm_group_label>Comparator Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Solid organ transplant recipient who has previously received Moderna vaccine at 0 and&#xD;
             1 months&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anaphylaxis or allergic reaction to Moderna vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepali Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital, Multi-Organ Transplant</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.</citation>
    <PMID>33378609</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Deepali Kumar</investigator_full_name>
    <investigator_title>Clinician-Investigator</investigator_title>
  </responsible_party>
  <keyword>solid organ transplant</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

